Targeting the regulatory mechanisms controlling the oncogenic functions of AARS1 and AARS2, particularly lactylation-related mechanisms, holds promising therapeutic potential for cancers but requires confronting challenges by developing isoform-specific and function-specific inhibitors. This evidence concerns the gene AARS1 and cancer.